Left ventricular hypertrophy and renin-angiotensin-aldosterone system: AT1-receptor blockers are in the focus

Abstract

Left ventricular hypertrophy (LVH) is one of the cardio-vascular continuum components, determining the prognosis of patient with essential hypertension (EH). Pathogenesis of LVH has a multifactor character. Important role in development of cardiomyocites hypertrophy, Intracardiac fibrosis, left ventricle cavity dilation belongs to renin-angiotensin-aldosteron system (RAAS). Pharmacologic blockade of RAAS composes the basis of therapy, directed to LVH regress. Application of Telmisartan is considered high-reasonable approach to treatment of EH-patient with LVH.

Keywords

• essential hypertension
• left ventricular hypertrophy
• renin-angiotensin-aldosteron system
• telmisartan